Select Language
COVID-19
The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global cardiac biomarkers market reached a value of US$ 9.0 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 14.9 Billion by 2027, exhibiting at a CAGR of 8.5% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Cardiac markers, also known as cardiac biomarkers, are released into the bloodstream when the heart is stressed, or its muscles are damaged. These markers include different types of enzymes, hormones, and proteins, such as cardiac troponins, creatine kinase (CK), ischemia-modified albumin (IMA), and myoglobin. Measurement and testing of these markers can help in diagnosing heart conditions like cardiac ischemia and acute coronary syndrome (ACS). At present, the triage and diagnostic systems used for determining the risk of these conditions are based on electrocardiograms (ECGs) and clinical history. However, these systems are insufficient and can lead to misdiagnosis or delay in treatment. As cardiac marker testing offers higher accuracy and can identify the conditions in the early stages of presentation, they are gaining traction across the globe. These markers can also help in monitoring the prognosis of these condition with greater accuracy and providing the most effective treatment to the patients.
www.imarcgroup.com
Note: Values and trends in the above chart consists of dummy data and are only shown here for representation purpose. Kindly contact us for the actual market size and trends.
To get more information about this market, Request Sample
Global Cardiac Biomarkers Market Drivers:
Over the past few years, there has been a rise in the number of patients suffering from ACS which has created a demand for cardiac marker testing at a global level. Other than this, rising awareness among patients and healthcare providers about the importance of early diagnosis of various CVDs is driving the demand for these markers. In addition, there are numerous private and public organizations which are investing in R&D activities to develop advanced technologies in the field of cardiac biomarkers. For instance, blood tests for high-sensitivity cardiac troponin I have been demonstrated to identify patients who are at a higher risk of a second heart attack. Moreover, high accuracy and rapid results offered by biomarker testing, coupled with the availability of affordable cardiac point-of-care testing, are some of the other factors which are contributing to the growth of the market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global cardiac biomarkers market, along with forecasts at the global and regional level from 2022-2027. Our report has categorized the market based on type, location of testing, and application.
Breakup by Type:
www.imarcgroup.com
Note: Values and trends in the above chart consists of dummy data and are only shown here for representation purpose. Kindly contact us for the actual market size and trends.
To get more information about this market, Request Sample
Based on the type, the market has been segmented into troponins (T and I), myocardial muscle creatine kinase (CK-MB), myoglobin, brain natriuretic peptide (BNPs) or NT-proBNP, ischemia modified albumin (IMA) and others.
Breakup by Location of Testing:
Based on the location of testing, the market has been segmented into laboratory testing and point of care testing. Laboratory testing currently accounts for a larger share.
Breakup by Application:
Based on the application, the market has been segmented into myocardial infarction, congestive heart failure, acute coronary syndrome, atherosclerosis and others. Myocardial infarction currently accounts for the highest share.
Regional Insights:
www.imarcgroup.com
To get more information on the regional analysis of this market, Request Sample
Region-wise, the market has been segmented into North America, Asia Pacific, Europe, Middle East and Africa, and Latin America. Amongst these, North America is the biggest market, accounting for majority of the global share.
Competitive Landscape:
The report has also analyzed the competitive landscape of the market with some of the key players being Abbott Laboratories, Alere Inc., Beckman Coulter, Becton, Dickinson And Co., Biomerieux, Bio-Rad Laboratories, Randox Laboratories, Roche Diagnostics Corporation, Siemens Healthcare and Thermo Fisher Scientific.
Report Coverage:
| Report Features | Details |
|---|---|
| Base Year of the Analysis | 2021 |
| Historical Period | 2016-2021 |
| Forecast Period | 2022-2027 |
| Units | US$ Billion |
| Segment Coverage | Type, Location of Testing, Application, Region |
| Region Covered | North America, Asia Pacific, Europe, Latin America, Middle East and Africa |
| Companies Covered | Abbott Laboratories, Alere Inc., Beckman Coulter, Becton, Dickinson And Co., Biomerieux, Bio-Rad Laboratories, Randox Laboratories, Roche Diagnostics Corporation, Siemens Healthcare and Thermo Fisher Scientific |
| Customization Scope | 10% Free Customization |
| Report Price and Purchase Option | Single User License $ 2499 Five User License $ 3499 Corporate License $ 4499 |
| Post-Sale Analyst Support | 10-12 Weeks |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
The global cardiac biomarkers market was valued at US$ 9.0 Billion in 2021.
We expect the global cardiac biomarkers market to exhibit a CAGR of 8.5% during 2022-2027.
The rising number of patients suffering from ACS due to shifting dietary patterns, coupled with the
increasing consumer awareness towards early diagnosis and treatment of cardiovascular diseases, is
currently driving the global cardiac biomarkers market.
The sudden outbreak of the COVID-19 pandemic had led to the postponement of several elective
surgeries pertaining to cardiac diseases to mitigate the risk of coronavirus infection upon hospital
visits.
Based on the location of testing, the global cardiac biomarkers market has been classified into
laboratory testing and point of care testing. Currently, laboratory testing holds largest market share.
Based on the application, the global cardiac biomarkers market can be bifurcated into myocardial
infarction, congestive heart failure, acute coronary syndrome, atherosclerosis, and others. Among
these, myocardial infarction accounts for the majority of the total market share.
On a regional level, the market has been classified into North America, Europe, Asia Pacific, Middle
East and Africa, and Latin America, where North America currently dominates the global market.
Some of the major players in the global cardiac biomarkers market include Abbott Laboratories,
Alere Inc., Beckman Coulter, Becton, Dickinson and Co., Biomerieux, Bio-Rad Laboratories, Randox
Laboratories, Roche Diagnostics Corporation, Siemens Healthcare, and Thermo Fisher Scientific.
10% Free customization
Purchase Options
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at
sales@imarcgroup.com